NO960221L - 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner - Google Patents

9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner

Info

Publication number
NO960221L
NO960221L NO960221A NO960221A NO960221L NO 960221 L NO960221 L NO 960221L NO 960221 A NO960221 A NO 960221A NO 960221 A NO960221 A NO 960221A NO 960221 L NO960221 L NO 960221L
Authority
NO
Norway
Prior art keywords
substituted
alkoxyphenyl
purin
ones
drugs
Prior art date
Application number
NO960221A
Other languages
English (en)
Norwegian (no)
Other versions
NO960221D0 (no
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO960221D0 publication Critical patent/NO960221D0/no
Publication of NO960221L publication Critical patent/NO960221L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO960221A 1995-01-19 1996-01-18 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner NO960221L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (2)

Publication Number Publication Date
NO960221D0 NO960221D0 (no) 1996-01-18
NO960221L true NO960221L (no) 1996-07-22

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960221A NO960221L (no) 1995-01-19 1996-01-18 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner

Country Status (30)

Country Link
US (1) US5866571A (fr)
EP (1) EP0722943A1 (fr)
JP (1) JPH08231546A (fr)
KR (1) KR960029335A (fr)
CN (1) CN1138583A (fr)
AR (1) AR002704A1 (fr)
AU (1) AU4097796A (fr)
BG (1) BG61729B1 (fr)
BR (1) BR9600149A (fr)
CA (1) CA2167349A1 (fr)
CO (1) CO4700524A1 (fr)
CZ (1) CZ16896A3 (fr)
DE (1) DE19501480A1 (fr)
EE (1) EE9600020A (fr)
FI (1) FI960226A7 (fr)
HR (1) HRP960009A2 (fr)
HU (1) HUP9600107A3 (fr)
IL (1) IL116771A (fr)
MA (1) MA23779A1 (fr)
NO (1) NO960221L (fr)
NZ (1) NZ280829A (fr)
PE (1) PE10597A1 (fr)
PL (1) PL312353A1 (fr)
SG (1) SG47379A1 (fr)
SK (1) SK7696A3 (fr)
SV (1) SV1996000004A (fr)
TN (1) TNSN96005A1 (fr)
TR (1) TR199600701A2 (fr)
YU (1) YU2896A (fr)
ZA (1) ZA96399B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
WO2003053975A1 (fr) * 2001-12-13 2003-07-03 Daiichi Suntory Pharma Co., Ltd. Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
WO2015200177A1 (fr) 2014-06-23 2015-12-30 Celgene Corporation Utilisation d'aprémilast pour le traitement d'une maladie hépatique ou d'une anomalie de la fonction hépatique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (fr) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
PE10597A1 (es) 1997-06-13
NO960221D0 (no) 1996-01-18
MA23779A1 (fr) 1996-10-01
NZ280829A (en) 1998-04-27
YU2896A (sh) 1999-03-04
CO4700524A1 (es) 1998-12-29
EE9600020A (et) 1996-08-15
HRP960009A2 (en) 1997-12-31
JPH08231546A (ja) 1996-09-10
EP0722943A1 (fr) 1996-07-24
AR002704A1 (es) 1998-04-29
IL116771A (en) 1999-06-20
PL312353A1 (en) 1996-07-22
CA2167349A1 (fr) 1996-07-20
ZA96399B (en) 1996-08-14
DE19501480A1 (de) 1996-07-25
SV1996000004A (es) 1997-02-19
FI960226A7 (fi) 1996-07-20
BR9600149A (pt) 1998-01-06
HU9600107D0 (en) 1996-03-28
FI960226A0 (fi) 1996-01-17
SG47379A1 (en) 1998-04-17
TNSN96005A1 (en) 2005-03-15
CZ16896A3 (en) 1996-08-14
IL116771A0 (en) 1996-05-14
SK7696A3 (en) 1996-08-07
KR960029335A (ko) 1996-08-17
HUP9600107A3 (en) 1999-06-28
AU4097796A (en) 1996-07-25
TR199600701A2 (tr) 1996-08-21
HUP9600107A2 (en) 1997-05-28
BG61729B1 (bg) 1998-04-30
CN1138583A (zh) 1996-12-25
BG100291A (bg) 1996-07-31
US5866571A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
BG98902A (bg) Имидазолови производни и тяхната употреба като инхибитори на цитокин
NO912151L (no) Essensiell-fettsyre-behandling.
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
BR0009719A (pt) Processo de tratamento
WO1998016507A3 (fr) Nouveaux derives de pyrazol heterocyclylmethyle-substitues
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
ITMI932571A0 (it) Estratti della cucurbita sp., procedimento per la loro produzione ed impiego nella medicina e nella cosmetica
NO954878L (no) Pyrrolderivater
EP1319402A4 (fr) INHIBITEURS DE PRODUCTION D'IgE
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
AR002704A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.
WO1998039293A3 (fr) 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
NO994822L (no) Immunotolerant protrombinkomplekspreparat
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
CA2163118A1 (fr) Fractions d'acide aurintricarboxylique et analogues avec activite anti-angiogenique; methodes d'utilisation
DK0808307T3 (da) Bicykliske isothiourinstofderivater, som kan anvendes ved terapi
NO951989D0 (no) Anvendelse av amidoaminer i öyepreparater
ES2088143T3 (es) Dispositivo y procedimiento que permiten la conformacion en frio de acanaladuras en la pared de una pieza de revolucion.
EE200100188A (et) Optiliselt aktiivne püridüül-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments